More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M,...

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M, boosted by strong organic growth and the positive impact of the Azur Pharma and EUSA Pharma acquisitions. The company guided FY12 revenues higher, now expecting revenue of $605M - $615M, versus the current consensus of $599.6M.